MAPT and Alzheimer disease: We performed bilateral injections of insoluble tau from AD brains (900 ng, AD-PHF in Figure 1A) in a transgenic rat model of tauopathy expressing human truncated tau aa151–391 with a Wistar-Kyoto and SHR background at the age of 3 months.